In our latest WTR Healthcare Happenings podcast, we welcome back Jack Lu, Director of Corporate Development at Ainos (NASDAQ: AIMD) to discuss key takes from the company's recently reported 3Q25 earnings release. He also dives into Ainos’ latest strategic partnerships with Topco and NEXCOM, its expanding IP moat with seven new patents, and outlines the roadmap for 2026—commercial scale-up, industrial deployments and expansion plans beyond Asia.
All content for WTR Healthcare Happenings is the property of Joe Brunetto and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In our latest WTR Healthcare Happenings podcast, we welcome back Jack Lu, Director of Corporate Development at Ainos (NASDAQ: AIMD) to discuss key takes from the company's recently reported 3Q25 earnings release. He also dives into Ainos’ latest strategic partnerships with Topco and NEXCOM, its expanding IP moat with seven new patents, and outlines the roadmap for 2026—commercial scale-up, industrial deployments and expansion plans beyond Asia.
PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL
WTR Healthcare Happenings
20 minutes
1 month ago
PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL
In this episode of WTR Healthcare Happenings, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores the evolving global regulatory environment for psychedelics—particularly MDMA—the ripple effects of the Lykos Therapeutics FDA Complete Response Letter (CRL) disclosures, and PharmAla’s strategic approach to research, manufacturing, and commercialization of clinical-grade MDMA and next-generation ...
WTR Healthcare Happenings
In our latest WTR Healthcare Happenings podcast, we welcome back Jack Lu, Director of Corporate Development at Ainos (NASDAQ: AIMD) to discuss key takes from the company's recently reported 3Q25 earnings release. He also dives into Ainos’ latest strategic partnerships with Topco and NEXCOM, its expanding IP moat with seven new patents, and outlines the roadmap for 2026—commercial scale-up, industrial deployments and expansion plans beyond Asia.
